The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Theravance Inc

Nasdaq: THRX
Last

(U.S.) $15.03

Today's change+0.48 +3.30%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Theravance Inc

Nasdaq: THRX
Last

(U.S.) $15.03

Today's change+0.48 +3.30%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Theravance Inc crosses above 50-day moving average

Theravance Inc closed up sharply Friday, rallying (U.S.)$0.48 or 3.30% to (U.S.)$15.03 and crossing above its 50-day moving average. Over the last five days, shares have lost 1.25% and are down 57.84% for the last year to date. This security has underperformed the S&P 500 by 69.36% during the last year.

Key company metrics

  • Open(U.S.) $14.67
  • Previous close(U.S.) $14.55
  • High(U.S.) $15.22
  • Low(U.S.) $14.53
  • Bid / Ask-- / --
  • YTD % change-57.84%
  • Volume362,893
  • Average volume (10-day)1,287,413
  • Average volume (1-month)983,690
  • Average volume (3-month)1,073,376
  • 52-week range(U.S.) $12.56 to (U.S.) $40.82
  • Beta1.93
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.00
  • Dividend yield6.65%
  • Trailing EPS(U.S.) -$0.98
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue11-12
Total other revenue--------
Total revenue11-12
Gross profit--------
Total cost of revenue--------
Total operating expense11111450
Selling / general / administrative991116
Research & development22334
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-10-10-15-48
Interest income (expense), net non-operating-12-10-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-22-20-16-50
Income after tax-21-20-16-50
Income tax, total0000
Net income-21-64-68-50
Total adjustments to net income--------
Net income before extra. items-21-20-16-50
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-21-20-16-50
Inc. avail. to common incl. extra. items-21-64-68-50
Diluted net income-21-64-68-50
Dilution adjustment0000
Diluted weighted average shares113111111109
Diluted EPS excluding extraordinary itemsvalue per share-0.19-0.18-0.15-0.46
Dividends per sharevalue per share0.250.000.00--
Diluted normalized EPSvalue per share-0.19-0.18-0.15-0.46